{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06336629",
      "orgStudyIdInfo": {
        "id": "WIN2023"
      },
      "organization": {
        "fullName": "Sun Pharmaceutical Industries Limited",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne",
      "officialTitle": "Combination Treatment of Winlevi With Duac Gel in Patients With Acne Vulgaris"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-06",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2023-11-15",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-07-10",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2024-07-10",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2024-03-11",
      "studyFirstSubmitQcDate": "2024-03-27",
      "studyFirstPostDateStruct": {
        "date": "2024-03-29",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-06-30",
      "resultsFirstSubmitQcDate": "2025-06-30",
      "resultsFirstPostDateStruct": {
        "date": "2025-07-17",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-06-30",
      "lastUpdatePostDateStruct": {
        "date": "2025-07-17",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Sun Pharmaceutical Industries Limited",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice."
    },
    "conditionsModule": {
      "conditions": [
        "Acne Vulgaris"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 10,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Winlevi (clascoterone) 1% & Duac gel",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: Winlevi (clascoterone) 1% & Duac gel"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Winlevi (clascoterone) 1% & Duac gel",
          "description": "Participants will use Winlevi (clascoterone) 1% and Duac gel as per label",
          "armGroupLabels": [
            "Winlevi (clascoterone) 1% & Duac gel"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.",
          "description": "The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne",
          "timeFrame": "Week 16"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Percent of Total Lesion Reduction at Week 16 Compared to Baseline",
          "timeFrame": "Week 16"
        },
        {
          "measure": "Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline",
          "timeFrame": "Week 16"
        },
        {
          "measure": "Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.",
          "timeFrame": "Week 16"
        },
        {
          "measure": "Tolerability Measures of Erythema Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" erythema at weeks 4,8,12 and 16",
          "timeFrame": "Week 4,8,12,16"
        },
        {
          "measure": "Tolerability Measures of Dryness Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" dryness at weeks 4,8,12 and 16.",
          "timeFrame": "Week 4,8,12,16"
        },
        {
          "measure": "Tolerability Measures of Peeling Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" peeling at weeks 4,8,12 and 16",
          "timeFrame": "Week 4,8,12,16"
        },
        {
          "measure": "Assessment of Skin Oiliness Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" oiliness at weeks 4,8,12 and 16",
          "timeFrame": "Week 4,8,12,16"
        },
        {
          "measure": "Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale",
          "description": "The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" burning at weeks 4,8,12 and 16",
          "timeFrame": "Week 4,8,12,16"
        },
        {
          "measure": "Tolerability Measures of Pruritus Based on 6-point Severity Scale",
          "description": "The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" Pruritus at weeks 4,8,12 and 16",
          "timeFrame": "Week 4,8,12,16"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\ni. Outpatient, male or female subjects of any race, and at least 12 years of age or older.\n\n* Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study:\n* A female is considered of childbearing potential unless she is:\n\n  1. postmenopausal for at least 12 months prior to study drug administration;\n  2. without a uterus and/or both ovaries; or\n  3. Has been surgically sterile for at least 6 months prior to study drug administration.\n* Reliable methods of contraception are:\n\n  1. Hormonal methods or intrauterine device in use \\> 90 days prior to study drug administration;\n  2. Barrier methods plus spermicide in use at least 14 days prior to study drug administration; or\n  3. Vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice).\n* Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.\n\nii. Facial acne IGA score of 3 or 4.\n\niii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.\n\nExclusion Criteria:\n\ni. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.\n\nii. Allergy or sensitivity to any component of the test medications. iii. Subjects who have not complied with the proper wash-out periods for prohibited medications .\n\niv. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.\n\nv. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse. vii. History of poor cooperation, non-compliance with medical treatment, or unreliability.\n\nviii. Exposure to an investigational drug study within 30 days of the Baseline Visit.\n\nix. Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4) â€¢ Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis)",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "stdAges": [
        "CHILD",
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Skin Sciences, PLLC",
          "city": "Louisville",
          "state": "Kentucky",
          "zip": "40217",
          "country": "United States",
          "geoPoint": {
            "lat": 38.25424,
            "lon": -85.75941
          }
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Winlevi (Clascoterone) 1% & Duac Gel",
          "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "9"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Winlevi (Clascoterone) 1% & Duac Gel",
          "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "9"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "33",
                      "spread": "17"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "calculatePct": false,
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.",
          "description": "The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "Percentage of patients",
          "timeFrame": "Week 16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "paramType": "two-sided",
              "paramValue": "100",
              "ciPctValue": "95",
              "ciNumSides": "TWO_SIDED"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percent of Total Lesion Reduction at Week 16 Compared to Baseline",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "Percent change",
          "timeFrame": "Week 16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "92",
                      "spread": "8.2"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "0.008",
              "statisticalMethod": "Wilcoxon (Mann-Whitney)"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "Percent change",
          "timeFrame": "Week 16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "96.4",
                      "spread": "6"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "0.007",
              "statisticalMethod": "Wilcoxon rank-sum test"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "Percent change",
          "timeFrame": "Week 16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "86.1",
                      "spread": "15.3"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "0.009",
              "statisticalMethod": "Wilcoxon rank sum test"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Tolerability Measures of Erythema Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" erythema at weeks 4,8,12 and 16",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Percentage of participant",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "66",
                      "lowerLimit": "31",
                      "upperLimit": "91"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88",
                      "lowerLimit": "51",
                      "upperLimit": "99"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88",
                      "lowerLimit": "51",
                      "upperLimit": "99"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88",
                      "lowerLimit": "51",
                      "upperLimit": "99"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "0.037",
              "pValueComment": "P-value from Baseline at Week 16",
              "statisticalMethod": "Wilcoxon signed rank",
              "statisticalComment": "P-value from Baseline at Week 16"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Tolerability Measures of Dryness Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" dryness at weeks 4,8,12 and 16.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Percentage of participant",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Tolerability Measures of Peeling Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" peeling at weeks 4,8,12 and 16",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "1",
              "pValueComment": "P-value from Baseline at Week 16",
              "statisticalMethod": "Wilcoxon signed rank"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Assessment of Skin Oiliness Based on 5-point Severity Scale",
          "description": "The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" oiliness at weeks 4,8,12 and 16",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "pValue": "1",
              "pValueComment": "P-value from Baseline at Week 16",
              "statisticalMethod": "Wilcoxon signed rank"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale",
          "description": "The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" burning at weeks 4,8,12 and 16",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88",
                      "lowerLimit": "51",
                      "upperLimit": "99"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Tolerability Measures of Pruritus Based on 6-point Severity Scale",
          "description": "The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition.\n\nThe information presented represents the \"Percentage of participant\" with \"Absent or Trace\" Pruritus at weeks 4,8,12 and 16",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of partiicipants",
          "timeFrame": "Week 4,8,12,16",
          "groups": [
            {
              "id": "OG000",
              "title": "Winlevi (Clascoterone) 1% & Duac Gel",
              "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "9"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 8",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88",
                      "lowerLimit": "51",
                      "upperLimit": "99"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 16",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "100",
                      "lowerLimit": "63",
                      "upperLimit": "100"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "16 weeks",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Winlevi (Clascoterone) 1% & Duac Gel",
          "description": "Winlevi (clascoterone) 1% \\& Duac gel: Participants will use Winlevi (clascoterone) 1% and Duac gel as per label",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 9,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 9,
          "otherNumAffected": 0,
          "otherNumAtRisk": 9
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictiveAgreement": true
      },
      "pointOfContact": {
        "title": "Head-Regulatory Affairs",
        "organization": "Sun Pharmaceutical Industries Limited",
        "email": "Clinical.Trial@sunpharma.com",
        "phone": "2266455645",
        "phoneExt": "5689"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2023-02-06",
          "uploadDate": "2025-06-30T05:11",
          "filename": "Prot_SAP_000.pdf",
          "size": 833658
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-12-02"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000152",
          "term": "Acne Vulgaris"
        }
      ],
      "ancestors": [
        {
          "id": "D017486",
          "term": "Acneiform Eruptions"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D012625",
          "term": "Sebaceous Gland Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C496269",
          "term": "Clascoterone"
        },
        {
          "id": "C466951",
          "term": "clindamycin phosphate benzoyl peroxide combination"
        }
      ]
    }
  },
  "hasResults": true
}